Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 9/20 | 0.54 |
| ▸ | NOS1 | P29475 | 4/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PAH | P00439 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL146837 | 0.93 | HPRT1 (0.58) | HPRT1NOS1USP2CASP7HSD17B10 | |
| SCHEMBL7192798 | 0.92 | HPRT1 (0.57) | HPRT1NOS1USP2CASP7HSD17B10 | |
| Water SCHEMBL10414024 | 0.92 | HPRT1 (0.57) | HPRT1NOS1USP2CASP7HSD17B10 | |
| SCHEMBL7197096 | 0.92 | HPRT1 (0.57) | HPRT1NOS1USP2CASP7HSD17B10 | |
| SCHEMBL10508833 | 0.89 | HPRT1 (0.55) | HPRT1NOS1USP2CASP7HSD17B10 | |
| Phosphoric Acid SCHEMBL1664405 | 0.88 | HPRT1 (0.62) | HPRT1 | |
| SCHEMBL10511442 | 0.87 | HPRT1 (0.53) | HPRT1NOS1CYP1A2 | |
| SCHEMBL10920053 | 0.86 | HPRT1 (0.56) | HPRT1NOS1USP2CASP7HSD17B10 | |
| SCHEMBL571080 | 0.84 | HPRT1 (0.60) | HPRT1NOS1USP2CASP7HSD17B10 | |
| SCHEMBL10916964 | 0.83 | HPRT1 (0.56) | HPRT1NOS1USP2CASP7HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190796-A1 | ENGINEERED CELLS EXPRESSING PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) OR A MODIFIED FORM THEREOF AND RELATED METHODS | JUNO THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | US | claimed |
| US-11253611-B2 | Thymidine kinase diagnostic assay for gene therapy applications | Genvivo, Inc. (US) | 2022-02-22 | — | — | US | claimed |
| EP-3607319-A1 | ENGINEERED CELLS EXPRESSING PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) OR A MODIFIED FORM THEREOF AND RELATED METHODS | Juno Therapeutics, Inc. (US) | 2020-02-12 | — | — | EP | claimed |
| CN-110730908-A | Engineered cells expressing Prostate Specific Membrane Antigen (PSMA) or modified forms thereof and related methods | 朱诺治疗学股份有限公司 | 2020-01-24 | — | — | CN | claimed |
| US-20190328904-A1 | THYMIDINE KINASE DIAGNOSTIC ASSAY FOR GENE THERAPY APPLICATIONS | Genvivo, Inc. | 2019-10-31 | — | — | US | claimed |
| US-10350302-B2 | Thymidine kinase diagnostic assay for gene therapy applications | Genvivo, Inc. (US) | 2019-07-16 | — | — | US | claimed |
| EP-2967078-B1 | THYMIDINE KINASE DIAGNOSTIC ASSAY FOR GENE THERAPY APPLICATIONS | GENVIVO INC (US) | 2018-10-17 | — | — | EP | claimed |
| WO-2018187791-A1 | ENGINEERED CELLS EXPRESSING PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) OR A MODIFIED FORM THEREOF AND RELATED METHODS | JUNO THERAPEUTICS, INC (US) | 2018-10-11 | — | — | WO | claimed |
| US-20180264137-A1 | THYMIDINE KINASE DIAGNOSTIC ASSAY FOR GENE THERAPY APPLICATIONS | Genvivo, Inc. | 2018-09-20 | — | — | US | claimed |
| US-9999683-B2 | Method for identifying and treating a patient having tumor lesions comprising administering a gene therapy retroviral vector particle comprising a mutated HSV-thymidine kinase (HSV-TK) polynucleotide | EPEIUS BIOTECHNOLOGIES CORPORATION (US) | 2018-06-19 | — | — | US | claimed |
| EP-2967078-A1 | THYMIDINE KINASE DIAGNOSTIC ASSAY FOR GENE THERAPY APPLICATIONS | Epeius Biotechnologies Corporation (US) | 2016-01-20 | — | — | EP | claimed |
| US-20140294772-A1 | THYMIDINE KINASE DIAGNOSTIC ASSAY FOR GENE THERAPY APPLICATIONS | EPEIUS BIOTECHNOLOGIES CORPORATION (US) | 2014-10-02 | — | — | US | claimed |
| WO-2014153205-A1 | THYMIDINE KINASE DIAGNOSTIC ASSAY FOR GENE THERAPY APPLICATIONS | EPEIUS BIOTECHNOLOGIES CORPORATION (US) | 2014-09-25 | — | — | WO | claimed |
| US-20250345409-A1 | COMPOSITIONS AND METHODS FOR THERAPEUTIC OR VACCINE DELIVERY | GENVIVO INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12350327-B2 | Compositions and methods for therapeutic or vaccine delivery | Genvivo, Inc. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250115930-A1 | COMPOSITIONS AND METHODS FOR THERAPEUTIC DELIVERY | Genvivo, Inc. | 2025-04-10 | — | — | US | disclosed |
| WO-2005023317-A1 | COMPOUNDS AND KITS FOR PREPARING IMAGING AGENTS AND METHODS OF IMAGING | GENERAL ELECTRIC COMPANY (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20050049487-A1 | Compounds and kits for preparing imaging agents and methods of imaging | GENERAL ELECTRIC COMPANY | 2005-03-03 | — | — | US | disclosed |
| US-20040166058-A1 | Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2004-08-26 | — | — | US | disclosed |
| WO-2004044227-A2 | ETHYLENEDICYSTEINE (EC)-DRUG CONJUGATES, COMPOSITIONS AND METHODS FOR TISSUE SPECIFIC DISEASE IMAGING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040166058-A1 | Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging | TEK, TIE1, CD40 | HPRT1 1625/4885NOS1 2917/4885CYP1A2 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.